David A. Siegel Alnylam Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 258,700 shares of ALNY stock, worth $71.1 Million. This represents 0.14% of its overall portfolio holdings.
Number of Shares
258,700
Previous 189,600
36.45%
Holding current value
$71.1 Million
Previous $28.3 Million
121.86%
% of portfolio
0.14%
Previous 0.07%
Shares
22 transactions
Others Institutions Holding ALNY
# of Institutions
614Shares Held
108MCall Options Held
2.33MPut Options Held
2.17M-
Capital World Investors Los Angeles, CA15MShares$4.12 Billion0.61% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.5MShares$3.44 Billion0.06% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.62 Billion0.05% of portfolio
-
Wellington Management Group LLP Boston, MA6.21MShares$1.71 Billion0.28% of portfolio
-
Baillie Gifford & CO6.03MShares$1.66 Billion1.16% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $33.8B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...